- Version 1.0
- Download 4
- File Size 917 MB
- File Count 1
- Create Date September 29, 2025
- Last Updated September 30, 2025
Clinical Utility of ctDNA-MRD in NSCLC: Real-World Insights and Case Applications
In this clinically focused presentation, Assoc. Prof. Le Thuong Vu explores the evolving role of ctDNA-based minimal residual disease (MRD) testing in the management of non-small cell lung cancer (NSCLC), offering practical insights from two compelling patient cases. The discussion emphasizes how serial ctDNA analysis can detect molecular progression well ahead of radiographic changes, enabling more proactive and targeted interventions.
Drawing on both metastatic and early-stage scenarios, Prof. Vu highlights how ctDNA-guided decisions—such as escalating therapy upon early molecular relapse or initiating adjuvant Osimertinib despite low-stage pathology (IA2)—can reshape treatment strategies. He also contrasts ctDNA with imaging-based RECIST criteria and reflects on the potential of MRD to improve response monitoring and recurrence risk assessment.
Through these real-world applications, this session underscores ctDNA-MRD as a promising tool for personalized, data-driven care in lung cancer, even as its use in NSCLC continues to evolve within clinical trials.
